Nanoparticle contrast agents for diagnostic imaging

Patent metadata

Field	Value
Publication number	US-9585974-B2
Application number	US-201615187115-A
Country	US
Kind code	B2
Filing date	Jun 20, 2016
Priority date	Dec 29, 2008
Publication date	Mar 7, 2017
Grant date	Mar 7, 2017

Abstract

Compositions of nanoparticles functionalized with at least one zwitterionic moiety, methods for making a plurality of nanoparticles, and methods of their use as diagnostic agents are provided. The nanoparticles have characteristics that result in minimal retention of the particles in the body compared to other nanoparticles. The nanoparticle comprising a nanoparticulate transition metal oxide covalently functionalized with a silane-functionalized non-targeting zwitterionic moiety.

First claim

The invention claimed is:

1. A nanoparticle composition comprising nanoparticles having structure IV, the nanoparticles comprising a functionalized nanoparticulate metal oxide and a trioxysilane betaine ligand

wherein R 2 is independently at each occurrence a C 1 -C 3 alkyl group; R 3 is independently at each occurrence a hydrogen or a C 1 -C 3 alkyl group; n is 0, 1, 2 or 3; q is 1, 2 or 3; and the functionalized nanoparticulate metal oxide comprises nanoparticulate tantalum oxide.

2. The nanoparticulate composition according to claim 1 , wherein each R 2 is methyl and each R 3 is hydrogen.

3. The nanoparticulate composition according to claim 1 , wherein each R 2 is methyl and each R 3 is methyl.

4. The nanoparticulate composition according to claim 1 , wherein n is 1, q is 1, and the functionalized nanoparticulate metal oxide consists essentially of nanoparticulate tantalum oxide.

5. The nanoparticulate composition according to claim 4 , wherein each R 2 is methyl and each R 3 is hydrogen.

6. A diagnostic imaging agent composition comprising nanoparticles having structure IV, the nanoparticles comprising a functionalized nanoparticulate metal oxide and a trioxysilane betaine ligand

wherein R 2 is independently at each occurrence a C 1 -C 3 alkyl group; R 3 is independently at each occurrence a hydrogen or a C 1 -C 3 alkyl group; n is 0, 1, 2 or 3; q is 1, 2 or 3; and the functionalized nanoparticulate metal oxide comprises nanoparticulate tantalum oxide.

7. The diagnostic imaging agent composition according to claim 6 , further comprising a pharmaceutically acceptable carrier or excipient.

8. The diagnostic imaging agent composition according to claim 6 , wherein the nanoparticles have a median particle size of up to 10 nm.

9. The diagnostic imaging agent composition according to claim 6 , wherein each R 2 is methyl and each R 3 is hydrogen.

10. The diagnostic imaging agent composition according to claim 6 , wherein each R 2 is methyl and each R 3 is methyl.

11. The diagnostic imaging agent composition according to claim 10 , wherein n is 1, q is 1, and the functionalized nanoparticulate metal oxide consists essentially of tantalum oxide.

12. The diagnostic imaging agent composition according to claim 6 , wherein the functionalized nanoparticulate metal oxide consists essentially of nanoparticulate tantalum oxide.

Assignees

• Gen Electric

Inventors

• Butts Matthew David
• Colborn Robert Edgar
• Bonitatibus Jr Peter John
• Torres Andrew Soliz

Classifications

• B82Y5/00

  Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery · CPC title

• Y10S977/773

  Nanoparticle, i.e. structure having three dimensions of 100 nm or less · CPC title

• A61K49/0428

  Surface-modified nanoparticles, e.g. immuno-nanoparticles · CPC title

• Y10S977/928

  X-ray agent · CPC title

• Y10S977/779

  Possessing nanosized particles, powders, flakes, or clusters other than simple atomic impurity doping · CPC title